Sang­amo lays off 160+ staffers, winds down fa­cil­i­ty, punts clin­i­cal pro­grams in dras­tic re­vamp

Months af­ter chop­ping about a quar­ter of its US work­force, Sang­amo Ther­a­peu­tics is back with an­oth­er round of lay­offs to tight­en its belt. As the Cal­i­for­nia biotech clos­es down a fa­cil­i­ty in Bris­bane ear­ly next year, it will be cut­ting an­oth­er 40% of the re­main­ing crew, or 162 roles.

Sang­amo says it’s look­ing to sim­pli­fy the or­ga­ni­za­tion and fo­cus on its epi­ge­net­ic reg­u­la­tion ther­a­pies to treat neu­ro­log­i­cal dis­eases, as well as AAV cap­sid de­liv­ery tech­nolo­gies. That will mean sus­pend­ing new in­vest­ment in and of­fload­ing two of its most ad­vanced pro­grams — in­clud­ing a gene ther­a­py for Fab­ry dis­ease and a CAR-Treg pro­gram for au­toim­mune con­di­tions, both of which are in Phase I/II tri­als.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER